Side-by-side · Research reference

CagrilintidevsMOTS-c

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED35/64 cited

BAnimal-StrongHUMAN-REVIEWED9/68 cited

Cagrilintide

Long-Acting Amylin Analogue · Phase 3

7.5%Additional weight loss vs semaglutideAhmed 2026

Once weeklyDosing frequencyBailey 2026

Dual AMYR/CTRReceptor agonismBailey 2026

SQ · Once WeeklyBailey 2026

MOTS-c

Mitokine · Mitochondria-Encoded

5–10 mgWeekly dose

AnimalEvidence levelLee 2015 Reynolds 2021

Min–hrsHalf-life

SQ · Variable · 2–3×/week

01Mechanism of Action

Parameter

Cagrilintide

MOTS-c

Primary target

Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026

Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015

Pathway

AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026

Folate cycle inhibition → ↑AICAR → AMPK phosphorylation → PGC-1α upregulationLee 2015 Kim 2018

Downstream effect

Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026 Yamauchi 2026

Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015

Feedback intact?

Yes — acts via physiological amylin pathways

Stress-responsive, AMPK-dependent nuclear translocationKim 2018

Origin

Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026

Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021

Antibody development

—

02Dosage Protocols

Parameter

Cagrilintide

MOTS-c

Standard dose (combination)

Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026

Phase 3 REDEFINE 5 trial dosing.

—

Monotherapy dosing

Dose-dependent, under investigation

Monotherapy trials reported in meta-analysis.

—

Frequency

Once weekly (subcutaneous)Bailey 2026

Long-acting formulation.

2–3× per week

Short half-life may necessitate more frequent dosing for saturation.

Evidence basis

Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026 Ahmed 2026

Animal + anecdotal

Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.

Duration

26–52 weeks in trialsYamauchi 2026

4–12 weeks (experimental)

Optimal cycle length unknown.

Route

Subcutaneous injectionBailey 2026

—

Standard dose

—

5–10 mg / week

Experimental, extrapolated from animal data. No human RCT-derived dose.

Lower / starter dose

—

2.5–5 mg / week

Recommended due to limited human data.

Reconstitution

—

Bacteriostatic water, 1–2 mL

10 mg/mL at 1 mL.

Timing

—

Pre-workout or fasted state preferred

Activity-context amplifies AMPK response.

Half-life

—

Minutes to hours (estimated)

Systemically unstable; native MOTS-c PK in humans not fully characterised.

03Metabolic / Fat Loss Evidence

Parameter

Cagrilintide

MOTS-c

Weight loss vs semaglutide

7.47% greater percentage weight lossAhmed 2026

CagriSema combination vs semaglutide monotherapy (meta-analysis).

—

Absolute weight change

Significantly greater absolute weight reductionAhmed 2026

Mean difference favoring combination therapy.

—

Mechanism

Central satiety inductionBailey 2026

—

BMI reduction

Significant BMI reduction vs comparatorAhmed 2026

—

Glycemic benefit

Reduced fasting glucose and HbA1cAhmed 2026

Synergistic effect with semaglutide in combination.

—

Lipid effects

Improvements in total cholesterol, LDL-C, HDL-C, VLDL-C, triglyceridesAhmed 2026

—

Body composition

Predominant fat loss with weight reduction

—

Mitochondrial function

In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026

C2C12 myotube study; clinical relevance under investigation.

—

Combination rationale

Multi-pathway approach: amylin (satiety) + GLP-1 (incretin)Lempesis 2026

—

Key publications

REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026 Ahmed 2026 Bailey 2026

—

Primary fat target

—

Diet-induced / metabolic obesity; systemic fat utilization

Quantified reduction

—

Significant HFD fat gain ↓Lee 2015

Murine models, dose-dependent (5 & 15 mg/kg).

IGF-1 impact

—

No direct IGF-1 pathway; AMPK-mediated

Effect on lean mass

—

High dose significantly ↑ lean mass in mice

Insulin sensitivity

—

Reversed HFD insulin resistance in 7 days (mice)

Triglycerides

—

AMPK-driven FA oxidation suggests TG benefit (not directly measured)

Glucose metabolism

—

Improved glucose tolerance; GLUT4 upregulation

Effect reversibility

—

Unknown — no long-term follow-up data

Context dependency

—

No effect in normal-chow mice; requires metabolic stress

Key publication

—

Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018

04Side Effects & Safety

Parameter

Cagrilintide

MOTS-c

Gastrointestinal

Nausea, diarrhea (common with incretin-based therapies)Pardali 2026

Dietary management and nutritional monitoring recommended.

—

Injection site reactions

Local reactions possible with subcutaneous administration

—

Safety profile

Generally consistent with incretin-based therapies

Phase 3 and meta-analysis safety data.

—

Tolerability

Tolerability considerations similar to GLP-1RAs

—

Muscle preservation

Lean mass considerations during weight loss

In vitro mitochondrial effects observed; clinical impact under investigation.

—

Injection site reaction

—

Mild irritation (reported)

Fluid retention / Edema

—

Not reported

Glucose intolerance

—

Improves glucose toleranceLee 2015

Cardiovascular

—

Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats

Cancer risk

—

Contradictory data — some models suggest pro-proliferative effects

CNS / Neurological

—

Insomnia, headache (anecdotal reports)

GI symptoms

—

Nausea, stomach discomfort (reported)

Antibody formation

—

No data (no long-term human trials)

Pregnancy / OB

—

Avoid — insufficient safety data

Evidence quality

—

Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021

Absolute Contraindications

Cagrilintide

·Hypersensitivity to cagrilintide or formulation components

MOTS-c

·Pregnancy / breastfeeding (insufficient data)

Relative Contraindications

Cagrilintide

·Severe gastrointestinal disease
·History of pancreatitis (incretin-based therapy consideration)

MOTS-c

·Active cancer or cancer predisposition
·AMPK pathway deficiency (efficacy nullified)
·Use with cancer-promoting medications (theoretical)

05Administration Protocol

Parameter

Cagrilintide

MOTS-c

1. Dosing frequency

Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026

Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.

2. Combination form

Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026 Bailey 2026

Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.

3. Injection site

Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.

Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.

4. Storage

Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.

Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.

5. Dietary considerations

Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026

27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.

06Stack Synergy

Cagrilintide

+ Semaglutide

Strong

View Semaglutide →

Cagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.

CagriSema: Cagrilintide 2.4 mg + Semaglutide 2.4 mg
Frequency: Once weekly subcutaneous
Duration: 26–52 weeks (trial data)
Primary benefit: Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation

Yamauchi 2026 Ahmed 2026 Bailey 2026

MOTS-c

+ Ipamorelin

Moderate

View Ipamorelin →

MOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.

MOTS-c: 5 mg SQ · pre-workout (2–3×/wk)
Ipamorelin: 200–300 mcg SQ · pre-sleep (daily)
Primary benefit: Metabolic flexibility + GH recovery + ROS reduction